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Abstract
Oesophageal adenocarcinoma (OAC) is an exemplar model of obesity-associated cancer. Response to
neoadjuvant chemoradiotherapy (NA CRT) is a clinical challenge. We examined if visceral adipose tissue and
obesity status alter radiosensitivity in OAC.
The radioresistant (OE33R) and radioresponsive (OE33P) OAC isogenic model was cultured with adipose
tissue conditioned media from three patient cohorts: non-cancer patients, surgery only OAC patients and NA
CRT OAC patients. Cell survival was characterised by clonogenic assay, metabolomic profiling by nuclear
magnetic resonance spectroscopy and adipokine receptor gene expression by qPCR. A retrospective in vivo
study compared tumour response to NA CRT in normal weight (n=53) versus overweight/obese patients
(n=148).
Adipose conditioned media (ACM) from all patient cohorts significantly increased radiosensitivity in
radioresistant OE33R cells. ACM from the NA CRT OAC cohort increased radiosensitivity in OE33P cells.
Metabolomic profiling demonstrated separation of the non-cancer and surgery only OAC cohorts and between
the non-cancer and NA CRT OAC cohorts. Gene expression profiling of OE33P versus OE33R cells
demonstrated differential expression of the adiponectin receptor-1 (AR1), adiponectin receptor-2 (AR2),
leptin receptor (LepR) and neuropilin receptor-1 (NRP1) genes. In vivo overweight/obese OAC patients
achieved an enhanced tumour response following NA CRT compared to normal weight patients. This study
demonstrates that visceral adipose tissue modulates the cellular response to radiation in OAC.
Key words: oesophageal cancer, obesity, radiotherapy, visceral adipose tissue

Introduction
Oesophageal adenocarcinoma (OAC) is an
aggressive disease with five-year survival rates of
approximately 20%, and 40% for patients who are
treated with curative intent (1). For locally advanced
disease, neoadjuvant chemoradiation (NA CRT) is
increasingly the standard of care (2-4). The CROSS
trial demonstrated that NA CRT followed by surgery
was associated with a greater than two-fold increase
in median overall survival compared with surgery
alone (2,3). A meta-analysis including CROSS and
eleven randomised controlled trials (RCTs) of
multimodal therapy compared with surgery alone
concluded that NA CRT was associated with a

significant improvement in overall survival (4).
Tumour response to NA CRT predicts survival, but
resistance to therapy remains a significant clinical
problem with only 14-45% of patients achieving a
complete pathological response (pCR) (2–4).
OAC is an examplar model of an obesityassociated cancer, and obesity may underlie the
marked increase in the incidence of OAC (1,5–7).
Although the epidemiologic association between
obesity and adenocarcinoma is well described, the
impact of obesity on tumour biology, response to
therapy, and outcomes, is unclear. Several studies
have shown that obesity is associated with increased
http://www.medsci.org
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risk of cancer recurrence and death, (8-10), while
others have reported no difference in survival
between obese and non-obese patients (11-14).
Importantly, obesity status may play differential roles
in tumour development during treatment and
following surgery.
The relationship between visceral adipose tissue
(VAT) and radioresponse has not been investigated.
The radioresistant phenotype is correlated with
features such as altered DNA repair (15), cell cycle
checkpoint operation (15), telomere biology (16), reactive oxygen species (ROS) biology (17), and induction
of apoptosis (15), all of which are hypothesized to be
affected by visceral adiposity. Obesity is associated
with a state of low-grade chronic inflammation that
causes systemic oxidative stress (18,19), a mechanism
by which ionizing radiation can damage cells (17).
Obesity is associated with alterations in DNA repair
mechanisms (20), and radioresistance of OAC is
associated with DNA damage repair efficiency (21).
Other putative mechanisms linking obesity and
aggressive tumour behaviour include adipokine
production, the insulin-like growth factor axis and sex
steroids (22). Alterations in tumour biology are
mediated not by adipocytes, but predominantly by
secreted factors from the adipose tissue stromal
vascular fraction (23). We have shown that visceral
adipose conditioned media (ACM) in OAC patients is
a rich source of adiponectin, leptin and VEGF (24),
and metabolomic profiling has demonstrated an
altered profile in ACM from viscerally obese
compared to non-obese OAC patients (25). This
current study assesses the interaction between obesity
and radioresponse in vitro and in vivo in OAC.

Methods
OAC tumour and adipose tissue biobank
Histologically proven OAC patients undergoing
surgical resection, and elective non-oncological
gastrointestinal surgeries were recruited to the study
with patient consent. Full ethical approval was
granted by the Adelaide and Meath Hospital
(incorporating the National Children’s Hospital)
(AMNCH) research ethics committee. Body weight,
height, visceral fat area (VFA) and central waist
circumference (WC) were measured. Body mass index
(BMI) was calculated as weight (kg)/ height2 (m2).
WC was measured to the nearest 0.1 cm using a tape
measure midway between the uppermost border of
the iliac crest and the lower border of the costal
margin in the midaxillary line after respiratory
exhalation while the patient was in a standing
position (26). VFA was calculated from a
pre-operative diagnostic computed tomography (CT)
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scan by an experienced radiologist, using a validated
technique (27,28). A VFA in excess of 163.8 cm2 (men)
and 80.1 cm2 (women) was classified as obese, or WC
in excess of 94cm (men) and 80cm (women) was used
where VFA wasn’t available (26). Standard operating
procedures for the collection, storage and analysis of
specimens were used (29).

Visceral adipose tissue processing and cell
co-culture with visceral ACM
Omental adipose tissues were excised at the
beginning of the surgical resections; adipose tissue
was minced, washed with sterile PBS, and cultured in
M199 media (Gibco) (5 g adipose tissue in 10mL
media) for 72 hours. The adipose tissue culture was
filtered to remove adipose tissue fragments and the
supernatant (ACM) stored at -80°C. The OE33P and
OE33R isogenic model of radioresistance were
cultured as previously described (21) and treated with
M199 control media or ACM at 37°C in 95%
humidified air and 5% CO2 for 24 hours.

Clonogenic assay to assess radiosensitivity
OE33P and OE33R cells were co-cultured for 24
hours with M199 control media or ACM, cells were
irradiated with 0 or 2 Gy X-ray radiation using a
Gulmay Medical X-ray generator, (RS225) (Gulmay
Medical), at a dose rate of 3.25 Gray (Gy) per minute.
Cells were cultured for 7–14 days to allow surviving
colonies to reach maximum density without merging
of colonies. Cells were stained with crystal violet dye
for 30 minutes, dye removed and colonies consisting
of 50 cells or more counted. Plating efficiencies (PE),
which are the fraction of colonies from untreated cells,
were calculated using the formula: PE= No. colonies/
No. cells seeded. The surviving fraction (SF), which is
the number of colonies produced after treatment,
expressed in terms of PE, was calculated using the
formula: SF= No. colonies/(No. cells seeded × PE).

Metabolomic profiling
A volume of 250 µL deuterium and 10 µL
sodium trimethyl [2,2,3,3-2H4] propionate (TSP) (0.005
g/mL) were added to each 300 µL ACM sample.
Spectra were acquired on a 600-MHz Varian nuclear
magnetic resonance (NMR) spectrometer (Varian
Limited, Oxford, United Kingdom) by using the first
increment of a NOESY (Nuclear overhauser effect
spectroscopy) pulse (sequence at 251C). 1H NMR
ACM spectra were processed with Chenomx software
(version 6; Chenomx Edmonton, Canada) and were
phase and baseline corrected. Spectra were integrated
into bins consisting of spectral regions of 0.001 ppm.
The water region was excluded, and data normalized
to the total area of the spectral integral. Discriminating metabolites were identified by using libraries of
http://www.medsci.org
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pure metabolites developed in-house and the Chenomx database library. Acquisition of samples resulted
in spectra containing a number of peaks, representing
proton resonance in 1H NMR.

Adipokine receptor gene expression following
co-culture with ACM
Following co-culture of OE33P and OE33R cells
with ACM, RNA was isolated using TriReagent and
reverse transcribed as previously described (25).
Adipokine gene expression (Adiponectin Receptor 1,
Adiponectin Receptor 2, Leptin Receptor, Neuropilin1), was measured by qPCR using a TaqMan® assay kit
(Applied Biosystems), and 18S was used as an
endogenous control for data normalisation. Analysis
was performed using SDS 2.3 and SDS RQ 1.2 relative
quantification software (Applied Biosystems). One
sample was set as the calibrator for analysis. Gene
expression was expressed as fold difference in
expression relative to control.

Retrospective analysis of patient associations
between obesity and radiation sensitivity
A retrospective analysis of patients with
resectable oesophageal or oesophagogastric junction
adenocarcinoma treated with NA CRT (neoadjuvant
chemoradiotherapy) at St. James’s Hospital was
performed. Clinical, pathological and survival data
were retrieved from our cancer database. All resected
tumours were staged in accordance with the American Joint Committee on Cancer (AJCC) (30). The
extent of residual carcinoma in the surgical specimen
was assigned a tumour regression grade (31). Tumour
regression grade (TRG) 1-3 was considered to
represent a good response to therapy, TRG 4-5 a poor
response to therapy. Response to therapy was also
classified accordinng to the modified Mandard
three-point TRG that distinguishes complete, partial,
and minimal or non-responders (32).

Statistical Analysis
Statistical analysis was performed using
Graphpad Prism 5 software and SPSS version 18 for
Windows software. Unless otherwise stated, data
were expressed as mean ± standard error of the mean
(SEM). Clinical data was expressed as the median.
Unpaired t-tests and the Mann-Whitney U test were
used to examine statistical significance between
unpaired groups of parametric and non-parametric
data respectively. Categorical variables were analysed
by Chi-square and Fisher’s exact tests. One-way
analysis of variance (ANOVA) and Tukey multiple
comparisons post-hoc test were performed where the
number of groups was three or more. RR refers to
relative risk, 95% CI to 95% confidence interval.
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Survival analysis was performed using Kaplan-Meier
curves and log-rank test and calculated from date of
diagnosis to the first event (recurrence, progression,
death or end of the follow-up period).
For metabolomic data analyses, multivariate
metabolite data analyses were performed with SimcaP+ software (version 11.0; Umetrics, Umea°, Sweden).
The 1H NMR spectra were analysed using two pattern
recognition methods; principal component analysis
(PCA) (unsupervised) sets to explore any overall
trends in the data; and partial least square discriminant analysis (PLS-DA). The variable importance in the
projection (VIP) value of each variable in the model
was calculated to indicate its contribution to the
classification of samples. Variables with a VIP value
>1.5 were considered important in discriminating
between groups. The quality of all models was judged
by the goodness-of-fit parameter (R2) and the predictive ability parameter (Q2), which is calculated by an
internal cross-validation of the data and the predictability calculated on a leave-out basis. For all analysis,
p ≤0.05 was considered to be statistically significant.

Results
Visceral ACM increases sensitivity to radiation
in OE33P and OE33R cells
Clonogenic assay was used to assess sensitivity
to 2 Gy X-ray radiation in OE33P and OE33R cells
following incubation with M199 control media or
ACM from non-cancer patients (non-cancer cohort,
n=5) (Figure 1A, B), ACM from OAC patients who
had not undergone NA CRT prior to surgery (surgery
only OAC cohort, n=14) (Figure 1C, D), and ACM
from OAC patients who received NA CRT therapy
prior to surgery (NA CRT OAC cohort, n=10) (Figure
1E, F). Anthropometric data for patient ACM used in
clonogenic assay is summarised in supplementary
table 1. OE33P cells incubated with ACM from the
non-cancer and surgery only OAC cohort did not
demonstrate any significant change in sensitivity to 2
Gy X-ray radiation, when compared to cells incubated
with M199 control media (Figure 1A and C). OE33P
cells treated with ACM from the NA CRT OAC cohort
demonstrated a statistically significant increase in
radiosensitivity to 2 Gy, when compared to cells
treated with M199 control media (p=0.009, Figure 1E).
Interestingly, OE33R cells were significantly more
radiosensitive following co-culture with ACM from
all three patient groups, the non-cancer cohort
(p=0.03, Figure 1B), the surgery only OAC cohort
(p=0.002, Figure 1D) and the NA CRT OAC cohort
(p<0.0001, Figure 1F), compared to cells treated with
M199 control media. Radiosensitivity was significantly increased in OE33R cells treated with ACM from
http://www.medsci.org
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NA CRT OAC patients compared to cells treated with
ACM from the radiation naïve OAC patient cohort
(p=0.003, Figure 1G). The ACM used in this study was
generated from obese and non-obese OAC patients,
but no differences in survival fractions of OE33P and
OE33R cells were observed when ACM from
non-obese compared to obese patients was analysed
(data not shown), indicating that it is the visceral
adipose tissue itself which can increase radiosensitivity, particularly in cells that are radioresistant.
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lines both at baseline and following co-culture with
ACM; adiponectin receptor 1 (AR1); adiponectin
receptor 2 (AR2); leptin receptor (LepR); and the
VEGF receptor neuropilin-1 (NRP1). Anthropometric
data for patient ACM used in these analyses is shown
in supplementary table 3.

Metabolomic profiling of ACM from three
patient cohorts
To investigate if the metabolites secreted in ACM
differ between the three patient cohorts, we performed metabolomic profiling of ACM using nuclear magnetic resonance spectroscopy (NMR). Anthropometric
data for patient ACM used in metabolomic screening
is summarised in supplementary table 2. A representtative PCA plot showing separation on the basis of the
three patient cohorts (non-cancer, surgery only OAC,
and NA CRT OAC patients) is depicted in Figure 2A
(R2=0.736). A robust PLS-DA model (Figure 2B) was
built to further explore the differences (R2=0.453, Q2=
0.235). To aid comparison and identification or
regions of difference a pairwise comparison was performed. The most influential peaks in the models were
identified and a metabolite assigned to each peak.
Semi-quantitative concentrations were compared
between groups for the most influential metabolites.
A PCA plot of 1H NMR ACM data for noncancer patients versus surgery only OAC patients
showed separation of the two cohorts, (R2=0.699,
Figure 2C). A PLS-DA model was built to compare
ACM profiles from the two cohorts (R2=0.479, Q2=
0.304, Figure 2D). Glucose was significantly increased
(p=0.019), whilst threonine (p=0.014) lysine, (p=0.017),
and valine (p=0.029) were all significantly decreased
in ACM from non-cancer patients, when compared to
surgery only OAC patients (Table 1A).
PCA and PLS-DA plots revealed separation
between ACM from non-cancer and NA CRT OAC
patients (Figure 2E, R2=0.0474, Q2=0.318). ACM from
non-cancer patients demonstrated significantly
increased glucose (p=0.012) but significantly
decreased threonine (p=0.005) lysine, (p=0.004), valine
(p=0.007), isoleucine (p=0.039) and glycine (p=0.05)
when compared to NA CRT OAC patients (Table 1B).

Adipokine receptor expression differs between
OE33P and OE33R at baseline and following
culture in visceral ACM
Gene expression of four adipokine receptors
representing abundant adipokines in non-obese and
obese VAT was assessed in OE33P and OE33R cell

Figure 1. ACM increases radiosensitivity in OE33P and OE33R. OAC
cells were treated with either M199 control media or ACM from non-cancer
patients (n=5), ACM from surgery only OAC patients (OAC patients who had
not undergone NA CRT) (n=14), or ACM from OAC patients who had
previously undergone NA CRT (n=10) for 24hrs, and sensitivity to 2 Gy X-ray
radiation was assessed. (A) Co-culture of OE33P cells with ACM from
non-cancer patients did not significantly alter radiosensitivity. (B) Co-culture of
OE33R cells with ACM from non-cancer patients significantly increased
radiosensitivity, when compared to M199 control media (p=0.03). (C) OE33P
cells treated with ACM from surgery only OAC patients did not demonstrate
significantly altered radiosensitivity. (D) OE33R cells treated with ACM from
surgery only OAC patients demonstrated significantly increased sensitivity to 2
Gy, when compared to M199 control media (p=0.002). (E) OE33P cells treated
with ACM from NA CRT OAC patients demonstrated significantly increased
sensitivity to 2 Gy, when compared to M199 control media (p=0.009). (F)
OE33R cells treated with ACM from NA CRT OAC patients demonstrated
significantly increased sensitivity to 2 Gy (p<0.0001), when compared to M199
control media. (G) OE33R cells treated with ACM from NA CRT OAC
patients showed significantly increased sensitivity to 2 Gy, when compared to
cells treated with ACM from surgery only OAC patients (p=0.003). Data are
expressed as mean ± SEM. Statistical analysis was performed using unpaired
student’s t test. Statistical analysis was performed using one-way ANOVA with
Tukey post-hoc correction. *p<0.05, **p<0.001, ***p<0.0001

http://www.medsci.org
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Table 1A. Metabolites discriminating non-cancer patients versus
surgery only OAC patients, and non-cancer patients versus NA
CRT OAC patients. A. VIPs generated from the PLS-DA of
non-cancer patients versus surgery only OAC patients
Non-cancer
ppm
1.305
1.865
3.845
1.035
3.515
1.315
1.325

VIP [1]
6.58509
2.22582
2.02298
1.95987
3.03494
7.33073
5.31929

Mean
0.0128
0.0019
0.0022
0.0011
0.0008
0.0492
0.0582

SD
0.0106
0.0014
0.0012
0.001
0.0003
0.0402
0.0484

Surgery only
OAC
Mean SD
0.0304 0.008
0.0039 0.0008
0.0005 0.0002
0.0027 0.0011
0.0019 0.0013
0.0827 0.0277
0.0834 0.0284

Metabolite
Threonine
Lysine
Glucose
Valine
Glycerol
Lactate
Lactate

P-value
0.014
0.017
0.019
0.029
NS
NS
NS

Glucose was significantly increased (p=0.019), whilst threonine (p=0.014) lysine,
(p=0.017), and valine (p=0.029) were all significantly decreased in ACM from
non-cancer patients, when compared to surgery only OAC patients.
VIP scores are indicated. For each metabolite, only peak is presented here. VIP=
Variable in the Projection; PLS-DA= Partial least square discriminant analysis;
PPM=Parts per million; NS=Non-significant

Table 1B. VIPs generated from the PLS-DA of non-cancer
patients versus NA CRT OAC patients
ppm
1.295
1.885
3.745
1.035
3.535
1.225
1.445

VIP [2]
5.67466
2.18606
2.09995
2.26945
5.24455
2.15509
3.68593

Non-cancer
Mean SD
0.0005 0.0061
0.0013 0.0005
0.0025 0.001
0.0011 0.001
0.0083 0.0076
0.0011 0.0017
0.0085 0.0072

NA CRT OAC
Mean SD
0.0114 0.0042
0.0029 0.001
0.0011 0.0002
0.0029 0.0008
0.0205 0.0111
0.003
0.0011
0.0023 0.0006

Metabolite
Threonine
Lysine
Glucose
Valine
Glycine
Isoleucine
Alanine

P-value
0.005
0.004
0.012
0.007
0.05
0.039
NS

ACM from non-cancer patients demonstrated significantly increased glucose
(p=0.012) but significantly decreased threonine (p=0.005) lysine, (p=0.004), valine
(p=0.007), isoleucine (p=0.039) and glycine (p=0.05) when compared to NA CRT
OAC patients. P-values are based on unpaired t-test.
VIP scores are indicated. For each metabolite, only peak is presented here. VIP=
Variable in the Projection; PLS-DA= Partial least square discriminant analysis; NA
CRT=Neoadjuvant chemoradiotherapy; PPM=Parts per million; NS=Non
significant

Expression of AR1 was significantly higher in
OE33P cells compared to OE33R cells at baseline
(p=0.008) (Figure 3A). There was a two-fold
downregulation in AR1 expression in OE33P cells
following 24 hours of ACM treatment compared to
cells treated with control media (p=0.019). ACM
treatment did not significantly alter AR1 expression in
OE33R cells (Figure 3B). Expression of AR2 was
significantly higher in OE33P cells compared to
OE33R cells at baseline (p=0.015) (Figure 3C). AR2
expression following ACM treatment was not altered
in OE33P or OE33R (Figure 3D).
Interestingly, levels of LepR were significantly
lower in OE33P cells compared to OE33R cells at
baseline (p=0.033) (Figure 3E). LepR expression was
five-fold lower in OE33P compared to OE33R cells
treated with ACM (p=0.0004), (Figure 3F). Levels of
NRP1 were also significantly lower in OE33P cells
compared to OE33R cells at baseline (p=0.038) (Figure
3G). ACM induced a 13-fold upregulation in NRP1

expression in OE33P cells (p=0.047), but did not alter
NRP1 expression in OE33R cells (Figure 3H).

Overweight and obese OAC patients
demonstrate enhanced radiosensitivity
compared to normal weight patients
Between 1990 and 2012, 201 consecutive OAC
patients completed neoadjuvant chemoradiotherapy
(NA CRT) as part of their curative therapy, and had a
surgical resection. Clinical and pathological data for
this cohort is summarised in supplementary table 4.
Overweight/obese patients were more likely to
have a lower pathological T stage at surgery following
NA CRT, when compared to normal weight patients,
(Relative Risk (RR) 1.495, 95% Confidence Interval
(CI) 1.094-1.938, p=0.02, Figure 4A), despite having
similar clinical T stages prior to NA CRT. The number
of lymph nodes analysed and lymph node positivity
did not differ between normal and overweight/obese
cohorts. Overweight/obese patients were more likely
to achieve a good TRG response (TRG1-3) compared
to normal weight patients (RR=2.141, 95%
CI=1.374-3.336, p=0.002, Figure 4B). When patients
with TRG 3 were excluded from the analysis,
overweight/obese patients were still more likely to
achieve a good (TRG 1-2) response following NA CRT
(RR=3.259, 95% CI=1.269-8.368, p=0.004, Figure 4C).
When classified according to the most recent TRG
stratification(29), overweight/obese patients were still
more likely to achieve a complete (TRG 1) or partial
(TRG 2-3) response following NA CRT (p=0.0025), but
the number of patients in each treatment response
group was small (Supplementary figure 1). When
classified into normal weight, overweight and obese
categories, overweight patients were more likely to
achieve a good (TRG 1-3) response following NA CRT
compared to normal weight patients (RR=2.147, 95%
CI=1.294-3.561, p=0.0041) (Supplementary figure 2A).
Obese patients were more likely to achieve a good
(TRG 1-3) response following NA CRT compared to
normal
weight
patients
(RR=2.130,
95%
CI=1.157-3.923, p=0.01), (Supplementary figure 2B).
There was no difference in TRG response in
overweight compared to obese patients (data not
shown).
Direct logistic regression was performed to
assess the impact of a number of factors on the
likelihood of a good TRG response. The model
contained six variables (age, gender, smoking history,
ASA grade, clinical T stage, BMI classification). Only
BMI classification independently predicted TRG
response. Overweight and obese patients were three
times more likely to achieve a good TRG response
after controlling for all other factors in the model
(OR=3.376, 95% CI=1.68-6.784, p=0.002). Obesity
http://www.medsci.org
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status was not associated with risk of recurrence and
did not affect survival (Figure 4D). Five-year survival
was 21%, with overall median disease-specific
survival of 27 months (median survival for normal
weight patients was 23 months, overweight/obese
median survival was 30 months).
Therefore, clinically we have shown that while
there was no difference in preoperative clinical T
stage between normal weight patients and
overweight and obese patients, overweight and obese
patients were more likely to have a lower pathological
T stage at surgery and to achieve a good TRG
response (TRG 1-3) to NA CRT. Obesity status did not
influence rates of postoperative morbidity, recurrence
or survival.

clinical challenge (1). Analysis of standard
clinicopathological parameters does not predict
response to NA CRT (30). This study demonstrates for
the first time a role for obesity in modulating response
to radiation. We show that radiosensitivity was
increased in radioresistant OE33R cells treated with
ACM, using ACM from three patient cohorts;
non-cancer patients, radiation naïve OAC patients,
and post NA CRT OAC patients. Therefore, increased
radiosensitivity is not merely a bystander effect
caused by previous exposure of the fat tissue to
radiation, but a response induced by factors from the
fat itself. However, radioresistance was lowest in cells
treated with ACM from patients who had received
NA CRT, suggesting that previous exposure to
irradiation may have influenced the visceral fat in
Discussion
these patients, generating a more radioresponsive
phenotype, mechanisms of which are unknown. As
Adenocarcinoma of the oesopahgus often
ACM from non-cancer patient and surgery only
presents late and confers a poor prognosis. Although
patients also decreased radioresistance in the
response rates to chemotherapy and radiation therapy
radioresistant cells, this suggest that factors in the
have improved, treatment resistance is a significant
ACM driving this effect are not present as a
consequence of malignancy, but may be
driven by the inflammatory nature of the
visceral fat tissue itself. Factors secreted
into the tumour microenvironment such as
cyclin D1, GDF-15, VEGF and MMP are
known to modulate the radioresponse
(34–37). Given the complexity of the
cellular response to ionizing radiation, it is
likely that multiple interacting processes
can regulate sensitivity to radiation.
Radioresistance was significantly
lower in OE33R cells treated with ACM
from NA CRT patients, compared to ACM
from the radiation naïve OAC cohort,
suggesting the ACM from these two
cohorts may have distinct metabolic
actions: previous radiation may have
stimulated the visceral fat to release
metabolites which could further alter the
radioresponse. Metabolomic profiling did
not demonstrate any difference in
metabolites between surgery only ACM
and NA CRT OAC patient ACM which
Figure 2. The metabolic profile is altered in ACM from non-cancer patients
compared to ACM from surgery only OAC patients and NA CRT OAC patients. (A)
might account for the difference in radioPrincipal component analysis (PCA) plot of NMR spectra from non-cancer patients (red triangles,
response seen in our isogenic model.
n=6), surgery only OAC patients (black triangles, n=6) and NA CRT OAC patients (blue
triangles, n=6), showed separation of the three patient cohorts (R2=0.736). (B) A partial
However, ACM from surgery only and NA
least-squares discriminant analysis (PLS-DA) of 1H NMR data from was constructed. Separation
CRT OAC patients was significantly
2
2
of the three cohorts was seen, but the model was weak, (R =0.453, Q =0.235). Therefore,
pairwise PCA and PLS-DA plots were constructed. (C) PCA plot of 1H NMR ACM data for two
altered compared to non-cancer patients.
patient cohorts (non cancer cohort versus surgery only OAC cohort), (R2=0.699). (D) PLS-DA
Higher levels of threonine, lysine and
of 1H NMR ACM data for non-cancer cohort versus surgery only OAC cohort, (R2=0.479,
2
2
Q =0.304). (E) PCA plot of non cancer patients versus NA CRT OAC patients (R =0.547). (F)
valine, and lower levels of glucose were
PLS-DA of 1H NMR plasma data for non-cancer cohort versus NA CRT OAC cohort, (R2=0.474,
seen in the metabolome of both surgery
Q2=0.318). A representative PCA and PLS-DA model showing separation of the surgery only
only and NA CRT OAC patients compared
OAC and NA CRT OAC cohorts was constructed, and separation of the two patient cohorts
was seen, but the Q2 value indicated that the model was weak (data not shown).
to non-cancer patients. A serum metabolite
http://www.medsci.org
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signature including elevated levels of threonine and
isoleucine predicted response to chemotherapy in
breast cancer patients (38). Metabolic profiling of
OAC patients demonstrated increased serum levels of
lysine and glucose in OAC patients, when compared
to healthy controls (39). Previous metabolomic
analysis of tumour tissue, serum and urine in
oesophageal cancer demonstrated variation in the
metabolites of glycolysis, lactic acid fermentation and

amino acid synthesis in oesophago-gastric cancer (40).
We have previously shown that altered energy
metabolism is associated with radioresistance in OAC
(41). Future analysis may allow identification of the
metabolic pathways in adipose tissue associated with
modulation of cancer risk in obese individuals. Mass
spectrometry- based metabolomics has demonstrated
utility for identifying biomarkers of ionizing radiation
exposure in cellular, mouse and rat in vivo radiation
models (42). In addition, metabolomic
mapping of ovarian, endometrial, lung, renal
and colorectal cancer have demonstrated
alterations in serum or urine profiles (43).
Systemic alterations in the metabolomic
profile of urine and serum may influence the
radioresponse in obese individuals; however
they cannot explain the local effect of ACM
on radioresponse in OAC cells, indicating
that other mechanisms must play a greater
role, possibly differential expression of
adipokine receptors.
Our study demonstrated that baseline
adipokine receptor expression differs
between OE33P and OE33R. AR1 and AR2
expression was higher in OE33P compared
to OE33R, while LepR and NRP1 expression
was lower in OE33P compared to OE33R.
Furthermore, following ACM treatment,
expression of LepR was higher in OE33R
compared to OE33P.
Adiponectin is the most abundant
adipokine (44), and over 90% of OACs
express AR1 and AR2 (45). High expression
of AR1 and AR2 is associated with prolonged survival in lung, thyroid and gastric
cancer (46–49). These findings are consistent
with our in vitro data demonstrating that
AR1 and AR2 levels are higher in radioresponsive compared to radioresistant
cancer. Adiponectin has been shown to
inhibit tumour growth in animals (44), and
recombinant
adiponectin
has
antiFigure 3. Adipokine receptor expression is altered in radioresistant OAC cells.
proliferative and proapoptotic effects on
Expression of a panel of adipokine receptors was assessed in OE33P and OE33R cell lines at
oesophageal adenocarcinoma cell lines that
baseline and following treatment with ACM from OAC patients, using qPCR. (A) Expression of
AR1 was significantly higher in OE33P compared to OE33R at baseline (p=0.008). (B) ACM
express both AR1 and AR2 (50, 51), which
induced a significant downregulation of AR1 expression in OE33P cells (p=0.019) but did not
may potentially contribute to delaying
alter AR1 expression in OE33R. (C) Basal AR2 expression is significantly increased in OE33P
recovery from DNA damage following
cells, when compared to OE33R (p=0.015). (D) No significant difference in AR2 expression
was demonstrated in OE33P or OE33R cells treated with ACM for 24 hours. (E) Basal LepR
irradiation, enhancing radiosensitivity.
expression was significantly lower in OE33P, when compared to OE33R (p=0.033). (F) ACM
Expression of LepR and NRP1 correltreatment did not alter LepR expression in OE33P. LepR expression was significantly increased
in OE33R cells following ACM treatment (p=0.006). LepR expression was significantly
ates with aggressive tumour behaviour in
increased in OE33R compared to OE33P cells treated with ACM (p=0.0004) (G) NRP1
OAC, and poor prognosis in a range of
expression was significantly lower in OE33P compared to OE33R (p=0.038). (H) ACM
significantly upregulated NRP1 expression in OE33P cells (p=0.047), however NRP1
cancers (45,52–59), however, their associaexpression in OE33R cells was not altered following ACM treatment. Data are expressed as
tion with radiosensitivity status has not been
mean ± SEM. Statistical analysis was performed using unpaired two-tailed student’s t-test to
investigated. We showed that LepR and
compare expression in OE33P versus OE33R and paired two-tailed student’s t-test to compare
ACM treated cells versus control; *p<0.05, **p<0.001, ***p<0.0001.
NRP1 are upregulated in radioresistant
http://www.medsci.org
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OAC. We and others have demonstrated that leptin
promotes cell proliferation, angiogenesis and
metalloproteinase expression in oesophageal and
colonic cancer cell lines (45,60–63). The obese db/db
mouse, which lacks a functional LepR, demonstrates
increased susceptibility to radiation (64), and leptin
upregulation is known to suppress therapy-induced
apoptosis by inhibiting caspase activation (65).
Our in vitro results demonstrating that ACM
influences radiosensitivity were further supported by
clinical data indicating an association between
increased adiposity and improved radioresponse.
Only 15-45% of patients undergoing NA CRT achieve
a complete pathologic response and subsequently,
have improved outcomes (66). It is not understood
why tumours of identical pre-treatment stage, undergoing identical neo-adjuvant regimens, respond
differently to NA CRT (66–70). Our study suggests
that BMI status influences tumour regression in OAC.
We have shown that patients who were overweight or
obese were more likely to have a lower pathological T
stage than normal weight patients, despite having
similar clinical T stages prior to treatment, and were
more likely to achieve a good tumour regression
grade than normal weight patients. Our results were
consistent across a number of TRG classification
systems. Shridhar et al. specifically examined
oncological and survival outcomes in a cohort of OAC
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patients who received NA CRT; BMI was not
associated with tumour response (13). In our study,
obesity status was not associated with recurrence or
survival. Four studies investigating outcomes in OAC
patients in relation to BMI have included a cohort of
patients who received NA CRT, none of which
demonstrated a difference in survival between obese
and non-obese patients (11-14). Improved TRG
outcome indicates improved locoregional controlhowever the effect on survival in obese patients may
be offset by associated morbidities, salvage systemic
therapies, early metastic events or treatment toxicity.
A limitation of this retrospective study is the use of
BMI obtained at the time of diagnosis, which might
not reflect changes in BMI that occurred before
diagnosis, and visceral fat area measurement of
obesity might have more closely mirrored the obesity
status (71–73) and should be the focus of future
studies.
Importantly, this study was strengthened by the
focus on a homogeneous patient population of
non-metastatic OAC patients that were all treated
with NA CRT followed by resection, reducing the
possibility of outcome differences due to stage or
treatment differences. Our findings linking obesity
and radiation response may translate into other
cancer types and outcomes.

Figure 4. Overweight/obese patients demonstrate enhanced response to NA CRT compared to normal weight OAC patients. (A) Normal weight
patients were more likely to have higher pathological T stage (T stage 3-4) at resection, following NA CRT, when compared to overweight/obese patients (RR=1.456,
95% CI=1.094-1.938, p=0.02). (B) Overweight/obese patients were twice as likely to achieve a good (TRG 1-3) response following NA CRT, when compared to
normal weight patients (RR=2.141, 95% CI=1.374-3.336, p=0.002). (C) When patients with TRG 3 were excluded from the analysis, overweight/obese patients were
three times as likely to achieve a good (TRG 1-2) response following NA CRT, when compared to normal weight patients (RR=3.259, 95% CI=1.269-8.368, p=0.004).
(D) There was no statistically significant difference in survival in normal weight compared to overweight/obese patients. Median survival was 23 and 30 months
respectively. Comparison of patient cohorts in terms of pathological T stage and TRG was performed using χ2 test. A p value of ≤0.05 was considered to be
statistically significant. *p<0.05, **p<0.001; RR=relative risk; 95% CI=95% confidence interval. Survival was calculated from date of diagnosis to the first event (i.e.
death or end of the follow-up period). Survival analysis was performed using Kaplan-Meier curves and log-rank test.
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Conclusions
This study suggests a link between obesity status
and response to radiation. Further work is warranted
to determine functionally the connection between
these two processes.
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